ISSUE 1308
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
The FDA has approved the proton-pump inhibitor (PPI) dexlansoprazole (Kapidex – Takeda), a delayed-release formulation of the R-enantiomer of lansoprazole (Prevacid – Takeda), for treating and maintaining healing of erosive esophagitis and for treatment of heartburn associated with non-erosive gastro-esophageal reflux disease (GERD). Both enantiomers of lansoprazole are active, but the R-enantiomer is longer acting.1 Lansoprazole is expected to become available generically later this year.2
FORMULATION — Kapidex is formulated as capsules containing dexlansoprazole in 2 types of enteric-coated granules that are soluble at 2 different pHs.The drug is designed to dissolve first in the proximal and then in the distal small intestine.
PHARMACOKINETICS — With a dose of 60 mg, serum concentrations of dexlansoprazole first reach a
... moreWould you like to read the rest of this article? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Article code: 1308a
Electronic, downloadable article - $45